PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.79%
Negative net income growth while CRVO stands at 17.10%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
1.20%
EPS growth under 50% of CRVO's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
2.99%
Diluted EPS growth under 50% of CRVO's 100.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
3.80%
Slight or no buybacks while CRVO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
6.10%
Slight or no buyback while CRVO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
35.18%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
35.60%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13691.29%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
29.84%
OCF/share CAGR of 29.84% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
58.26%
3Y OCF/share CAGR of 58.26% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-7976.92%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
76.35%
Net income/share CAGR of 76.35% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
62.71%
3Y net income/share CAGR of 62.71% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
1259.19%
Equity/share CAGR of 1259.19% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
224.33%
Equity/share CAGR of 224.33% while CRVO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-84.52%
Negative 3Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.68%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D growth drastically higher vs. CRVO's 16.72%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-32.93%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.